TABLE 6

Impact of PET on Intended Management for Restaging by Cancer Type^*

Cancer type	No. of scans	% of cases with change in management^†	95% CI	Imaging-adjusted impact (%)^‡	95% CI
Ovary	1,971	37.7	35.6–39.8	13.0	11.6–14.5
Prostate	1,477	34.0	31.6–36.4	13.5	11.7–15.2
Small cell lung	1,357	40.8	38.2–43.4	14.2	12.4–16.1
Bladder	1,239	36.4	33.7–39.1	13.6	11.7–15.5
Uterus	1,064	30.5	27.8–33.3	11.7	9.7–13.6
Pancreas	1,021	38.3	35.3–41.3	11.3	9.3–13.2
Myeloma	1,009	46.4	43.3–49.5	10.8	8.9–12.7
Kidney	979	34.4	31.4–37.4	12.8	10.7–14.9
Stomach	916	35.5	32.4–38.6	13.4	11.2–15.6
Connective tissue	450	28.0	23.9–32.1	9.1	6.5–11.8
Nonmelanoma skin	363	23.1	18.8–27.5	6.3	3.8–8.8
Cervix	353	26.9	22.3–31.5	10.5	7.3–13.7
Liver and intrahepatic bile ducts	260	41.9	35.9–47.9	16.2	11.7–20.6
Leukemia	229	36.7	30.4–42.9	14.8	10.2–19.5
Gallbladder	215	38.6	32.1–45.1	13.5	8.9–18.1
Thyroid	203	34.5	27.9–41.0	10.8	6.6–15.1
All other	1,478	33.2	30.8–35.6	12.9	11.1–14.6
Total	14,584	35.9	35.1–36.7	12.6	12.0–13.1

↵* Specific cancer types are listed when there were at least 200 cases.
↵† Defined as change from treatment to nontreatment or as change from nontreatment to treatment.
↵‡ No benefit from PET was assumed for cases with imaging plan before PET.